Fig. 1
From: Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Progression-free survival (PFS) of CDK4/6 inhibitors in clinical trials. Upper and lower panels are referred to endocrine-sensitive and endocrine-resistant settings, respectively
